Download PDF
Thromb Haemost 1986; 55(02): 222-227
DOI: 10.1055/s-0038-1661526
Original Article
Schattauer GmbH Stuttgart

Peripheral Venous Plasma Aspirin Concentrations and Platelet Aggregation Inhibition Produced by Enteric-Coated Aspirin Formulations

Roslyn A Brandon
*   The Department of Medicine, University of Oueensland, Royal Brisbane Hospital, Herston, Reckitt
,
J A G Emmett
*   The Department of Medicine, University of Oueensland, Royal Brisbane Hospital, Herston, Reckitt
,
M J Eadie
*   The Department of Medicine, University of Oueensland, Royal Brisbane Hospital, Herston, Reckitt
,
A C W Curran
**   The Department of Colman, Pharmaceutical Division, Sydney, Australia
,
I H Bunce
***   The Department of Pathology, Royal Brisbane Hospital, Herston, Australia
› Author Affiliations
Further Information

Publication History

Received 30 July 1985

Accepted 06 February 1986

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a random cross-over design, six healthy consenting adult volunteers were given on separate occasions single doses of 300-650 mg of 3 different formulations of enteric-coated aspirin. Over various intervals for 48-54 h following dosage, plasma aspirin and salicylate concentrations were measured together with percentage inhibition of platelet aggregation activated by threshold concentrations of sodium arachidonate alone and combined with ADP and collagen. In all subjects each formulation delivered measurable quantities of aspirin to the peripheral circulation, the unchanged drug being detected at various times up to and including 28 h after dosage. Moreover, low aspirin concentrations were found to co-exist with unimpaired platelet aggregation. All 3 formulations yielded statistically significant (P <0.01) inhibition of platelet aggregation activated both by arachidonate and by the combination of aggregants when tested 24-29 and 48-54 h after dosage; there were no significant differences (P >0.05) between the 3 formulations in this regard. Two different patterns of delivery of unchanged aspirin to the systemic circulation from these enteric-coated formulations were apparent. These patterns may be important when considering which aspirin formulation might be most appropriate in chronic use for an antiplatelet effect. None of the enteric-coated formulations used in this study may be optimal in this regard.

Key words

Enteric-coated aspirin - Platelet aggregation - Thromboembolism
 

  • References

  • 1 Stubbe L, Th FL, Pietersen JH, van Heulen C. Aspirin preparations and their noxious effect on the gastrointestinal tract. Br Med J 1962; II: 675-680
    PubMedGoogle Scholar
  • 2 Roberts MS, McLeod LJ, Cossum PA, Vial JH. Inhibition of platelet function by a controlled release acetylsalicylic acid formulation - single and chronic dosing studies. Eur J Clin Pharmacol 1984; 27: 67-74
    CrossrefPubMedGoogle Scholar
  • 3 Rehders K, Simrock R, Spahn H, Mutschler E, Breddin HK. Plasma salicylate levels and platelet function after acute and chronic administration of slow-release acetylsalicylic acid (Monobeltin). Eur J Clin Pharmacol 1985; 27: 683-687
    CrossrefPubMedGoogle Scholar
  • 4 Britton M, Melander A, Svensson J, Wahlin-Boll E. Platelet aggregation and plasma levels of acetylsalicylic acid in stroke patients on longterm treatment with an enteric-coated aspirin formulation. Eur J Clin Pharmacol 1984; 27: 363-365
    CrossrefPubMedGoogle Scholar
  • 5 Brantmark B, Wahlin-Boll E, Melander A. Bioavailability of acetylsalicylic acid and salicylic acid from rapid - and slow - release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 1982; 22: 309-314
    PubMedGoogle Scholar
  • 6 Ross-Lee LM, Elms MJ, Cham BE, Bochner F, Bunce IH, Eadie MJ. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 1982; 23: 545-551
    CrossrefPubMedGoogle Scholar
  • 7 Ali M, McDonald J WD, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9-13
    CrossrefPubMedGoogle Scholar
  • 8 Pedersen AK, Fitzgerald GA. Dose related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. New Eng J Med 1984; 311: 1206-1211
    PubMedGoogle Scholar
  • 9 Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367-374
    CrossrefPubMedGoogle Scholar
  • 10 Brandon RA, Eadie MJ, Smith MT. A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. Ther Drug Monit 1985; 7: 16-21
    PubMedGoogle Scholar
  • 11 Vanderhoek JY, Makheja AN, Baily JM. Inhibition of fatty acid oxygenases by onion and garlic oils - evidence for the mechanism by which these oils inhibit platelet aggregation. Biochem Pharmacol 1980; 29: 3169-3173
    CrossrefPubMedGoogle Scholar
  • 12 Cham BE, Ross-Lee L, Bochner F, Imhoff D. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit 1980; 2: 365-372
    CrossrefPubMedGoogle Scholar
  • 13 Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 297-299
    CrossrefPubMedGoogle Scholar
  • 14 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632
    PubMedGoogle Scholar
  • 15 Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979; 63: 532-535
    CrossrefPubMedGoogle Scholar